Prodrug and antedrug: Two diametrical approaches in designing safer drugs

Archives of Pharmacal Research

Volumn 25, Issue 2, 2002, Pages 111-136

  Lee, Henry J ^a   Cooperwood, John S ^a   You, Zhengqing ^a   Ko, Dong Hoon ^a   Pyoung, Han Hwang ^b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b Chonbuk National University   (South Korea)

Author keywords

Antedrug; Anti inflammation; Antibody directed enzyme prodrug; Asthma; Gene directed enzyme prodrug; Nucleoside prodrug; Nucleotide prodrug; Pro antedrug; Prodrug

Indexed keywords

ANTIBODY CONJUGATE; CYTOSINE DEAMINASE; DEAMINASE; FLUCYTOSINE; GANCICLOVIR; NUCLEOSIDE; NUCLEOTIDE; PRODRUG; THYMIDINE KINASE;

DRUG DESIGN; GENE THERAPY; GENETICS; REVIEW;

CYTOSINE DEAMINASE; DRUG DESIGN; FLUCYTOSINE; GANCICLOVIR; GENE THERAPY; IMMUNOCONJUGATES; NUCLEOSIDE DEAMINASES; NUCLEOSIDES; NUCLEOTIDES; PRODRUGS; THYMIDINE KINASE;

EID: 0036545413     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02976552     Document Type: Review

References (196)

1. Aghi, M., Kramm, C. M., Chou, T. C., Breakefield, X. O., and Chiocca, E. A., Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine deaminase gene therapies. J. Natl. Cancer Inst., 90, 370-380 (1998).
2. Albert, A., Chemical aspects of selective toxicity. Nature, 182, 421-423 (1958).
3. Arimilli, M. N., Kim, C. U., Dougherty, J., Mulato, A., Oliyai, R., Shaw, J. P., Cundy, K. C., and Bischofberger, N., Synthesis, In Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Prodrugs . Antiviral Chem. Chemother., 8, 557-564 (1997).
4. Austin, E. A. and Huber B. E., A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of E. coli cytosine deaminase. Mol. Pharmacol. 43, 380-387 (1993).
5. Avery, M. A. and Woolfrey, J. R., Antiinflammatory steroids. In Wolff, M.E. (Ed.), Medicinal Chemistry and Drug Discovery. John Wiley &Sons, Inc. 281-376 (1997).
6. Bagshawe, K. D. and Begent, R. H. J., First clinical experience with ADEPT. Adv. Drug Delivery Rev., 22, 365-367 (1996).
7. Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Rogers, G. T., Antibody-Directed Enzyme Prodrug Therapy (ADEPT): a review of some theoretical, experimental and clinical aspects. Analytical Oncology, 5, 879 (1994).
8. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Shama, S. K., Melton, R. G., and Sherwood, R. F., A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 58, 700-703 (1988).
9. Balzarini, J., Aquaro, S., Perno, C. -F., Witvrouw, M., Holy, A., and De Clerq, E., Activity of the (R)-Enantiomers of 9-(2-Phosphonylmethoxypropyl) adenine and 9-(2-Phosphonylmethoxypropyl)-2,6-Diaminopurine Against Human Immunodeficiency Virus in Different Human Cell Systems. Biochem. Biophys. Res. Comm., 219, 337-341 (1996).
10. Balzarini, J., Egberink, H., Hartmann, K., Cahard, D., Vahlenkamp, T., Thormar, H., De Clercq, E., and McGuigan, C., Antiretrovirus Specificity and Intracellular Metabolism of 2′,3′-Didehydro-2′,3′- dideoxythymidine (Stavudine) and Its 5-Monophosphate Triester Prodrug So324. Mol. Pharmacol., 50, 1207-1213 (1996b).
11. Balzarini, J., Egberink, H., Hartmann, K., Karlsson, A., Perno, C.F., Cahard, D., Naesens, L., Thormar, E., De Clercq, E., and McGuigan, C., Mechanism of Anti-HIV Action of Masked Alaninyl 2′,3′-Dideoxy-2,3- Didehydrothymidine 5-Monophosphate Derivatives. Antiviral Res., 30, A18 (1996d).
12. Balzarini, J., Holy, A., Jindrich, J., Naesens, L., Snoeck, R., Schols, D., De Clercq E., Differential Antiherpesvirus and Antiretrovirus Effects of the (S) and ® Enantiomers of Acyclic Nucleoside Phosphonates: Potent and Selective In Vitro and In Vivo Antiretrovirus Activities of (R)-9-(2- Phosphonylmethoxypropyl)-2,6-Diaminopurine. Antimicrob. Agents and Chemother., 37, 332-338 (1993).
13. Balzarini, J., Karlsson, A., Aquaro, S., Perno, C.F., Cahard, D., Naesens, L., De Clercq, E., and McGuigan, C., Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc, Natl. Acad. Sci. USA, 93, 7295-7299 (1996a).
14. Balzarini, J., Kruining, J., Wedgwood, O., Pannecouque, C., Aquaro, S., Perno, C. F., Naessens, L., Witvrouw, M., Heijtink, R., De Clercq, E., and McGuigan, C., Conversion of 2′,3′-Dideoxyadenosine (ddA) and 2′,3′-Didehydro-2′,3′-dideoxyadenosine (d4A) to Their Corresponding Aryloxyphosphoramidate Derivatives Markedly Potentiates Their Activity Against Human Immunodeficiency Virus and Hepatitis B Virus. FEBS Letters, 410, 324-328 (1997).
15. Balzarini, J., Naesens, L., Slachmuylders, J., Niphuis, H., Rosenburg, I., Holy, A., and Schellekens, H., De Clerq, E., 9-(2-Phosphonylmehtoxyethyl) adenine (PMEA) Effectively Inhibits Retrovirus Replication In Vitro and Simian Immunodeficiency Virus Infection in Rhesus Monkeys. AIDS, 5, 21-28 (1991).
16. Balzarini, J., Wedgwood, O., Kruining, J., Pelemans, H., Heijtink, R., De Clercq, E., and McGuigan, C., Anti-HIV and Anti-HBV Activity and Resistance Profile of 2′,3′-Dideoxy-3′-Thiacytidine (3TC) and Its Arylphosphoramidate Derivative CF 1109. Biochem. Biophys. Res. Comm., 225, 363-369 (1996c).
17. Barnes, P. J., Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clinical Science, 94, 557-572 (1998).
18. Beaucamp, L. M., Orr, G. F., de Miranda, P., Burnette, T., and Krenitsky, T. A., Amino Acid Ester Prodrugs of Acyclovir. Antiviral Chem. Chemother., 3, 157-164 (1992).
19. Beltinger, C., Fulda, S., Kammertoens, T., Uckert, W., and Debatin, K. M., Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res., 60, 3213-3217 (2000).
20. Bentires-Alj, M., Hellin, A. C., and Lechanteur, C., Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther., 7, 20-26 (2000).
21. Benzaria, S., Pélicano, H., Johnson, R., Maury, G., Imbach, J. L., Aubertin, A. M., Obert, G., and Gosselin, G., Synthesis, In Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy) ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability. J. Med. Chem., 39, 4958-4965 (1996).
22. Biggadike, K., Angell, R. M., Burgess, C. M., Farrell, R. M., Hancock, A. P., Harker, A. J., Irving, W. R., Ioannou, C., Procopiou, P. A., Shaw, R. E., Solanke, Y. E., Singh, O. M. P., Snowden, M. A., Stubbs, R. J., Walton, S., and Weston, H. E., Selective plasma hydrolysis of glucocorticoid g-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J. Med. Chem., 43, 19-21 (2000).
23. Biggadike, K., Lynn, S. M., Procopiou, P. A., Shaw, R. E., and Williamson, C. J. Chem. Soc., Perkin Trans. 1, 813-818 (2000).
24. Blakey, D. C., Valcaccia, B. E., East, S., Wright, A. F., Boyle, F. T., Springer, C. J., Burke, P. J., Melton, R.G., and Bagshawe, K.D., Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell. Biophys., 22, 1-8 (1993).
25. Bloch, A., Robins, M. J., and McCarthy, J. R., Jr., The role of the 5-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase. J. Med. Chem., 10, 908-912 (1967).
26. Bodey, G. P., Freireich, E. J., Monto, R. W., and Hewlett, J. S., Cytosine Arabinoside (NSC-63878) Therapy For Acute Leukemia in Adults. Cancer Chemother. Rep., 53, 59 (1969).
27. Bodor, N. and Buchwald, P., Soft drug design: general principles and recent applications. Med. Res. Rev., 20(1), 58-101 (2000).
28. Bodor, N., Recent advances in retrometabolic drug design and targeting approaches. Pharmazie, 55(3), 163-166 (2000).
29. Boyd, M. R., Bacon, T. H., and Sutton, D., Antiherpesvirus Activity of 9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in Animals. Antimicrob. Agents Chemother., 32, 358-363 (1988).
30. Boyd, M. R., Bacon, T. H., and Sutton, D., Comparative Activity of Penciclovir and Acyclovir in Mice Infected Intraperitoneally with Herpes Simplex Virus Type 1 SC 16. Antimicrob. Agents Chemother., 37, 642-645 (1993).
31. Bronson, J. J., Ghazzouli, I., Hitchcock, M. J. M., Russel, J. W., Klunk, L. J., Kern E. R., and Martin, J. C., In vivo Anti-retrovirus and Anti-cytomegalovirus Activity of 9-((2-Phosphonylmethoxy)-ethyl)adenine (PMEA). Abstracts of Papers; 5th International Conference on AIDS, Montreal, Canada, Abstract M.C.P. 74 (1989).
32. Brouilette, G., Kawamura, M., Kumar, G. N., and Bodor, N., Soft drugs. 21. Design and evaluation of soft analogs of propantheline. J. Pharm. Sci. 85, 619 (1996).
33. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmannn, J. L., and Klatzmann, D., Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90, 7024-7028 (1993).
34. Chu, C. K., Bhadti, V. S., Doshi, K. J., Etse, J. T., Gallo, J. M., Boudinot, F. D., and Schinazi, R. F., Brain Targeting of Anti-HIV Nucleosides: Synthesis and In Vitro and In Vivo Studies of Dihydopyridine Derivatives of 3-Azido-2,3-dideoxyuridine and 3-Azido-3-deoxythymidine. J. Med. Chem., 33, 2188-2192 (1990).
35. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M., In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science, 256, 1550-1552 (1992).
36. Dayer, P., Kubli, A., Kupfer, A., Courvoisier, F., Balant, L., and Fabre, J. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolizers. Br. J. Clin. Pharmacol., 12, 750-751 (1982).
37. De Clerq, E., Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurine and pyrimidines. Biochem. Pharmacol., 42, 963-972 (1991).
38. De Miranda, P., Blum, M. R., Pharmacokinetics of Acyclovir After Intranvenous and Oral Administration. J. Antimicrob. Chemother., 12 (Suppl. B) 29-37 (1983).
39. Dessolin, J., Vlieghe, P., Bouygues, M., Medou, M., Quélé ver, G., Camplo, M., Chermann, J. C., and Kraus, J. L., Tri-N-Boc- Tetraazamacrocycle-Nucleoside Conjugates: Synthesis and Anti-HIV Activities. Nucleosides & Nucleotides, 17, 957-968 (1998).
40. Domin, B. A., Mahony, W. B., and Zimmerman, T. P., Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol., 46, 503-510 (1993).
41. Elion, G. B., The biochemistry and mechanism of action of acyclovir. Antimicrob. Chemother., 12, Suppl. B:9-17 (1983).
42. Elshami, A. A., Saavedra, A., Zhang, H., Kucharczuk, J. C., Spray, D. C., Fishman, G. I., Amin, K. M., Kaiser, L. R., and Albeda S. M., Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase ganciclovir system in vitro. Gene Ther., 3, 85-92 (1996).
43. Eltahir, A., Heys, S. D., Hutcheon, A. W., Sarkar, T. K., Smith, I., Walker, L. G., Ah-See, A. K., and Eremin, O., Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am. J. Surg., 175, 127-132 (1998).
44. Erhardt, P. W., Woo, C. M., Gorzynski, R. J., and Anderson, W. G., Ultrashort-acting b-adrenergic blocking agent. 1. (Aryloxy)-propanolamines containing esters in the nitrogen substituent. J. Med. Chem., 25, 1402-1407 (1982).
45. Farquhar, D., Khan, S., Srivastva, D. N., and Saunders, P. P., Synthesis and Antitumor Evaluation of Bis[(Pivaloyloxy)methyl]-2-Deoxy-5-Fluorouridine 5-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells. J. Med. Chem., 37, 3902-3909 (1994).
46. Filer, C. W., Allen, G. D., and Brown, T. A., Metabolic and Pharmacokinetic Studies Following Oral Administration of 14C-Famciclovir to Healthy Subjects. Xenbiotica, 24, 357-368 (1994).
47. Fiorino, T., Current and future treatment of inflammatory bowel disease. Drug & Market Development. 42-48 (2000).
48. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N., The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53, 5274-5283 (1993).
49. Freeman, S. M., McCune, C., Robinson, W., Abboud, C. N., Abraham, G. N., Angel, C., and Marrogi, A., The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum. Gene Ther., 6, 927-939 (1995).
50. Freeman, S. M., Ramesh, R., and Marrogi, A. J., Immune system in suicide gene therapy. Lancet, 349, 2-3 (1997).
51. Fridland, A., Robbins, B. L., Srinivas, R. V., Arimilli, M., Kim, C., and Bischofberger, N., Antiretroviral Activity and Metabolism of bis(POC)PMPA, an Oral Bioavailable Prodrug of PMPA. Antiviral Res., 34, A49, 27 (1997).
52. Friend, D. R., Phillips, S., and Tozer, T. N., Colon-specific drug delivery from a glucoside prodrug in the guinea pig. Efficacy study. J. Control Release, 15, 47-54 (1991).
53. nd ed., Messerli, F. H., Ed.; W. B. Saunders Co., New York, 465-474 (1996).
54. Ge, K., Xu, L., Zheng, Z., Xu, D., Sun, L. and Liu, X., Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int. J. Cancer, 71, 675-679 (1997).
55. Geddes, D. M., Inhaled corticosteroids: Benefits and risks. Thorax, 47, 404-407 (1992).
56. Giradet, J. L., Gosselin, G., Périgaud, C., Balzarini, J., De Clercq, E., and Imbach, J. -L., Nucleosides & Nucleotides, 14, 645-647 (1995a).
57. Girardet, J. L., Périgaud, C., Aubertin, A.M., Gosselin, G., Kirn, A., and Imbach, J. L., Bioorg. Med. Chem. Lett., 5, 2981-2984 (1995b).
58. Hamamoto, U., Nakashima, H., Matsui, A., Matsuda, A., Ueda, T., and Yamamoto, N., Inhibitory Effects of 2′,3′-Didehydro-2′, 3′-Dideoxynucleosides on Infectivity, Cytopathic Effects and Replication of Human Immunodeficiency Virus. Antimicrob. Agents Chemother., 31, 908 (1987).
59. Hamamoto, U., Nakashima, H., Matsui, A., Matsuda, A., Ueda, T., and Yamamoto, N., Inhibitory Effects of 2′,3′-Didehydro-2′, 3′-Dideoxynucleosides on Infectivity, Cytopathic Effects and Replication of Human Immunodeficiency Virus. Antimicrob. Agents Chemother., 31, 908 (1987).
60. Hamilton, T. C. and Parkes, M. W., Bufuralol, a new betaadrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: Pharmacology. Arzneim.-Forsch. 27, 1410-1417 (1977).
61. Hanna, N. N., Mauceri, H. J., Wayne, J. D., Hallahan, D. E., Kufe, D. W., and Weichselbaum, R. R., Viral directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res., 57, 4205-4209 (1997).
62. Harden, M. R., Jarvest, R. L., Boyd, M. R., Sutton, D., and Vere Hodge, R. A., Prodrugs of Selective Antiherpesvirus Agent 9-[4-Hydroxy-3- (hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties. J. Med. Chem., 32, 1738-1743 (1989).
63. Harnden, M. R., Jarvest, R. L., Bacon, T. H., and Boyd, M. R., Synthesis and Antiviral Activity of 9 [4-Hydroxy-3-(hydroxymethyl) but-1-yl]purines J. Med. Chem., 30, 1636-1642 (1987).
64. Harnden, M. R., Jarvest, R. L., Boyd, M. R., Sutton, D., and Vere Hodge, R. A., Prodrugs of the Selective Antiherpesvirus Agent 9-[4-Hydroxy-3- (hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties. J. Med. Chem., 33, 1765-1773 (1989a).
65. Harnden, M. R., Jarvest, R. L., Boyd, M. R., Sutton, D., Vere and Hodge, R. A., Prodrugs of the Selective Antiherpesvirus Agent 9-[4-Hydroxy-3- (hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties. J. Med. Chem., 32, 1738-1743 (1989b).
66. Heiman, A. S., Hickman, F., Ko, D. -H., and Lee, H. J., New steroidal anti-inflammatory antedrugs bind to macrophage glucocorticoid receptors and inhibit nitric oxide generation. Steroids, 63, 644-649 (1998).
67. Heiman, A. S., Ko, D.-H., Chen, M., and Lee, H. J., New steroidal anti-inflammatory antedrugs: Methyl 3,20-dioxo-9α-fluoro-11β, 17α,21-trihydroxy-1,4-pregnadiene-16α-carboxylate and methyl 21-acetyloxy-3,20-dioxo-11β,17α-dihydroxy-9α-fluoro-1, 4-pregnadiene-16a-carboxylate. Steroids, 62, 491-499 (1997).
68. Higuchi, T. and Stella, V., Eds. ACS Symp. Ser., no. 14 (1975).
69. Holland, J. F. and Glidewell, O., Complementary Chemotherapy in Acute Leukemia. Recent Results Cancer Res., 30, 95 (1970).
70. Hong, C. I., Kirisitis, A. J., Buchheit, D. J., Nechaev, A., and West, C. R., 1β-D-Arabinofuranosylcytosine Conjugates of Thioether Phospholipids as a New Class of Potential Antitumor Drugs. Cancer Drug Delivery, 3, 101-113 (1986).
71. Hong, C. I., Nechaev, A., Kirisits, A. J., Vig, R., West, C. R., Manouilov, K. K., and Chu, C. K., Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Thioether Phospholipids. J. Med. Chem., 39, 1771-1777 (1996).
72. Hong, C. I., Nechaev, A., and West, C. R., Nucleoside Conjugates as Potential Antitumor Agents. 2. Synthesis and Biological Activity of 1-(β-D-Arabinofuranosyl)cytosine Conjugates of Prednisolone and Prednisone. J. Med. Chem., 22, 1428-1432 (1979a).
73. Hong, C. I., Nechaev, A., and West, C. R., Nucleoside Conjugates as Potential Antitumor Agents. 2. Synthesis and Biological Activity of 1-(β-D-Arabinofuranosyl)cytosine Conjugates of Prednisolone and Prednisone. J. Med. Chem., 22, 1428-1432 (1979b).
74. Hortobagyi, G. N., Anthracyclines in the treatment of cancer: an overview. Drugs, 54, 1-7 (1997).
75. Hostetler, K. Y., Richman, D. D., Sridhar, C. N., and Gardner, M. F., Antiviral Activity of Phosphatidyl-dideoxycytidine in Hepatitis B Infected Cells and Enhanced Hepatitic Uptake in Mice. Antiviral Res., 24, 59-67 (1994).
76. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S., Metabolism of 5 fluorocytosine in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 91, 8302-8306 (1994).
77. Huber, B. E., Austin, E. S., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A., In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53, 4619-4626 (1993).
78. Hwang, S. K., Juhasz, A., Yoon, S. H., and Bodor, N., Design, synthesis and evaluation of soft bufuralol analogues. J. Med. Chem., 43(8), 1525-1532 (2000).
79. Ichikawa, T., Tamiya, T., Adachi, Y., Ono, Y., Matsumoto, K., Furuta, T., Yoshida, Y., Hamada, H., and Ohmato, T., In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther., 7, 74-82 (2000).
80. Ji Y., Moog, C., Schmitt, G., Bischoff, P., and Luu, B., Monophosphoric Acid Diesters of 7b Hydroxycholestrol and of Pyrimidine Nucleosides as Potential Antitumor Agents: Synthesis and Preliminary Evaluation of Antitumor Activity. J. Med. Chem., 33, 2264-2270 (1990).
81. Ji, F., Huang, F., Juhasz, A., Wu, W., and Bodor, N., Design, synthesis and evaluation of soft glycopyrrolate and its analog. Pharmazie., 55(3), 187-191 (2000).
82. Jones, R. J., Arimilli, M. N., Lin, K. -Y., Louie, M. S., McGee, L. R., Shaw, J. -P., Burman, D., Lee, M., Kennedy, J. A., Prisbe, E. J., Bischofberger, N., Lee, W. A., and Cundy, K. C., Abstract Op11; XII International Roundtable Nucleosides, Nucleotides and their biological Application, September 15-19, La Jolla, USA (1996).
83. Juhasz, A. and Bodor, N., Cardiovascular studies on different classes of soft drugs. Pharmazie., 55(3), 228-238 (2000).
84. Kanai, F., Lan, K. H., Shiratori, Y., Tanaka, T., Ohashi, M., Okudaira, T., Yoshida, Y., Wakimoto, H., Hamada, H., Nakabayashi, H., Tamaoki, T., and Omata, M., In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirusmediated transfer of cytosine deaminase gene. Cancer Res., 57, 461-465 (1997).
85. Kaneko, Y. and Tsukamoto, A., Gene therapy of hepatoma: bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett., 96, 105-110 (1995).
86. Kerr, D. E., Schreiber, G. J., Vrudhula, V. M., Svensson, H. P., Hellstrom, I., Hellstrom, K. E., and Senter, P. D., Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs . Cancer Res., 55, 3558-3563 (1995).
87. Khalil, M. A., Kwon, T., and Lee, H. J., A novel approach to the development of safer anti inflammatory steroids: Antedrugs. Current Topics in Med. Chem., 1, 173-202 (1993).
88. Khalil, M. A., Maponya, M. F., Ko, D. -H., You, Z., Oriaku, E. T., and Lee, H. J., New antiinflammatory steroids: [16αa,17α-d]-3- hydroxyiminoformylisoxazoline derivatives of prednisolone and 9α-fluoroprednisolone. Med. Chem. Res., 6, 52-60 (1996).
89. Kimura, T., Yamaguchi, T., Usuki, K., Kurosaki, Y., Nakayama, T., Fujiwara, Y., Matsuda, Y., Unno, K., and Suzuki, T., Colonic mucosa-specific pro-antedrugs for oral treatment of ulcerative colitis: design, synthesis and fate of methyl 20-glucopyranosyloxyprednisolonates. J. Control Release, 30, 125-135 (1994).
90. Klatzmann, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhatari, K., Diquet, B., Salzmann, J. L., and Philippon, J., A phase I/II study of herpes simplex type 1 thymidine kinase "suicide" gene therapy recurrent glioblastoma, Hum. Gene Ther., 9, 2595-2604 (1998).
91. Ko, D.-H., Heima, A. S., Chen, M., and Lee, H. J., New steroidal anti-inflammatory antedrugs: Methyl 21-desoxy-21-chloro-11β,17α- dihydroxy-3,20-dioxo-1,4-pregnadiene-16α-carboxylate, methyl 21-desoxy-21-chloro-11β-hydroxy-3,20-dioxo-1,4-pregnadiene-16α- carboxylate, and their 9α-fluoro derivatives. Steroids, 65, 210-218 (2000).
92. Ko, D. -H., Heiman, A. S., Hudson, C. E., and Lee, H. J., New steroidal antiinflammatory antedrugs: Methyl 3,20-dioxo-9α-fluoro-11β, 17α,21-trihydroxy-1,4-pregnadiene-16α-carboxylate and its 21-O-acyl derivatives. Steroids, in the press (2001).
93. Ko, D. -H., Maponya, M. F., Khalil, M. A., Oriaku, E. T., You, Z. and Lee, H. J., New anti inflammatory steroids: [16α,17α-d]-isoxazoline derivatives of prednisolone and 9α-fluoroprednisolone. Med. Chem. Res., 7, 313-323 (1997).
94. Kodama, K., Morozumi, M., Saitoh, K., Kuninaka, A., Yoshino, H., and Saneyoshi, M., Antitumor Activity and Pharmacology of 1-β-D- Arabinofuranosylcytosine-5-stearylphosphate: An Orally Active Derivative of 1-b-D-Arabinofuranosylcytosine. Jpn. J. Cancer Res., 80, 679 (1989).
95. Kuriyama, S., Mitoro, A., Yamazaki, M., Tsujinoue, H., Nakatani, T., Akahane, T., Toyokawa, Y., Kojima, H., Okamoto, S., and Fukui, H., Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand. J. Gastroenterol., 34, 1033-1041 (1999).
96. Kwon T, Heiman A. S., Oriaku E. T., Yoon, K., and Lee, H. J., New steroidal antiinflammatory antedrugs: steroidal [16α, 17α-d]-3- carbethoxyisoxazolines. J. Med. Chem., 38, 1048-1051 (1995).
97. Labaree, D. C., Reynolds, T. Y., and Hochberg, R. B., Estradiol-16a-carboxylic acid esters as locally active estrogens. J. Med. Chem., 44, 1802-1814 (2001).
98. Lee, H. J. and Ko, D. -H., A novel approach to the discovery of non-systemic anti-inflammatory steroids: Antedrug. Arch. Pharm. Res., 22(3), 279-287 (1999).
99. Lee, H. J. and Soliman, M. R. I., Anti-inflammatory steroids without pituitary adrenal suppression. Science, 215, 989-991 (1982).
100. Lee, H. J., You, Z., Ko, D. -H., and McLean, H. M., Recent advances in prodrugs and antedrugs. Drug Discovery and Development, 1(2), 235-244 (1998).
101. Lee, H. J., You, Z., Ko, D. -H., and Yoon, K. J., New steroidal anti-inflammatory agents: Prednisolone derivatives with an isoxazoline fusion at the 16- and 17-carbons and an alkyl carboxylate at the 16a-position. Drugs Exptl. Clin. Res., 24(2), 57-66 (1998).
102. Lefebvre, I., Périgaud, C., Pompon, A., Aubertin, A. M., Girardet, J.L., Kirn, A., Gosselin, G., and Imbach, J. L., Mononucleoside Phosphotriester Deravitives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3-Azido-2,3-dideoxythymidine 5-Monophosphate. J. Med. Chem., 38, 3941-3950 (1995).
103. Lewis, L. D., Fowle, A. S. E., and Bittiner, S. B., Human Gastrointestinal Absorption of Acyclovir from Tablet Duodenal Infusion and Sipped Solution. Br. J. Clin. Pharmacol., 21, 459-462 (1986).
104. Lipworth, B. J., Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch. Intern. Med., 159(9), 941-955 (1999).
105. Lorey, M., Meier, C., De Clerq, E., and Balzarini, J., New Synthesis and Antitumor Activity of CycloSal-Derivatives of 5-Fluoro-2′- deoxyuridinemonophosphate. Nucleosides & Nucleotides, 16, 789-792 (1997).
106. Lowenthal, R. M. and Eaton, K., Toxicity of chemotherapy. Dematol. Oncol. Clin. North Am., 10, 967-990 (1996).
107. Manouilov, K. K., Fedorov, I. I., Boudinot, F. D., White, C. A., Kotra, K. P., Schinazi, R. F., Hong, C. I., and Chu, C. K., Lymphatic Targeting of Anti-HIV Nucleosides: Distribution of 3-Azido-3-Deoxythymidine (AZT) and 3-Azido-2,3-Deoxyuridine (AzdU) after Administration of Dipalmitoylphosphatidyl Prodrugs to Mice. Antiviral Chem. Chemother., 6, 230-238 (1995).
108. Manouilov, K. K., Xu, Z. S., Boudinot, F. D., Schinazi, R. F., and Chu, C. K. Lymphatic Targeting of Anti-HIV Nucleosides: Distribution of 2′,3′-Dideoxyinosine after Intravenous and Oral Administration of Dipalmitoylphosphatidyl Prodrug in Mice. Antiviral Res., 34, 91-99 (1997).
109. Mar, E, C., Chiou, J. F., Cheng, Y. C., and Huang, E. S., Human cytomegalovirus-indeced DNA polymerase and its interaction with the triphosphates of 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-5- methyuracil, -5-iodocytosine, and 5-methylcytosine. J. Virol., 56, 846-851 (1995).
110. Martin-du Pan, R. C., Vonlanthen, M. C., and Dubuis, J. M., Growth and collagen synthesis disorders in asthmatic children treated with inhaled steroids. Rev. Med., Suisse Romande, 119(6), 475-479 (1999).
111. McGuigan, C., Cahard, D., Sheeka, H. M., De Clercq, E., and Balzarini, J., Aryl Phosphoramidate Derivatives of d4T Have Improved Anti-HIV Efficacy in Tissue Culture and May Act by the Generation of a Novel Intracellular Metabolite. J. Med. Chem., 39, 1748-1753 (1996).
112. McGuigan, C., Camarasa, M. J., Egberink, H., Hartmann, K., Karlsson, A., Perno, C. F., and Balzarini, J., Design, synthesis and biological evaluation of novel nucleotide prodrugs as inhibitors of HIV replication. Int. Antiviral News, 5, 19-21 (1997a).
113. McGuigan, C., Pathirana, R. N., Balzarini, J., and De Clercq, E., Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT. J. Med. Chem., 36, 1048-1052 (1993).
114. McGuigan, C., Tsang, H.-W., Cahard, D., Turner, K., Velazquez, S., Salgado, A., Bidois, L., Naesens, L., De Clercq, E., and Balzarini, J., Phosphoramidates Derivatives of d4T as Inhibitors of HIV: The Effect of Amino Acid Variation. Antiviral Res., 35, 195-204 (1997b).
115. McLean, H. M., Heiman, A. S., and Lee, H. J., Synthesis and pharmacological evaluations of novel conjugates of steroidal antedrugs and non-steroidal anti-inflammatory drugs . Med. Chem. Res., submitted (2001).
116. Meier, C. 4H-1.3.2.-Benzodioxaphosphorin-2-nucleosyl-2-oxide A New Concept for Lipophilic, Potential Prodrugs of Biologically Active Nucleoside Monophosphates. Angew. Chem., 108, 77-79 (1996).
117. Meier, C., De Clerq, E., and Balzarini, J., Cyclo-Saligenyl-3′- azido-2′,3′-dideoxythymidine monophosphate (CycloSal-AZTMP) A New Pro-nucleotide Approach. Nucleosides and Nucleotides, 16, 793-796 (1997c).
118. Meier, C., Knispel, T., De Clerq, E., and Balzarini, J., ADA-Bypass by Lipophilic CycloSal-ddAMP Pro-nucleotides a Second Example of the Efficiency of the CycloSal-concept. Bioorg. Med. Chem. Lett., 7, 1577-1582 (1997d).
119. Meier, C., Knispel, T., De Clerq, E., and Balzarini, J., CycloSal-pronucleotides of 2′,3′-Dideoxyadenosine and 2′,3′-Dideoxy-2′,3′-didehydroadenosine: Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System. J. Med. Chem., 42, 1604-1614 (1999a).
120. Meier, C., Knispel, T., Lorey, M., and Balzarini, J., CycloSal-Pronucleotides: The Design and Biological Evaluation of a New Class of Lipophilic Nucleotide Prodrugs. Int. Antiviral News, 5, 183-186 (1997a).
121. Meier, C., Knispel, T., Marquez, V. E., Siddiqui, M. A., De Clerq, E., and Balzarini, J., CycloSal-Pronucleotides of 2-Fluoroara-and 2-Fluoro-ribo-2,3-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade. J. Med. Chem., 42, 1615-1624 (1999b).
122. Meier, C., Lorey, M., De Clerq, E., and Balzarini, J., Cyclic Saligenyl Phosphotriesters of 2′,3′-Dideoxy-2′,3′- didehydrothymidine (d4T)-A New Pro-nucleotide Approach. Bioorg. Med. Chem. Lett., 7, 99-104 (1997b).
123. Meier, C., Lorey, M., De Clerq, E., Balzarini, J., CycloSal-2′, 3′-dideoxy-2′,3′-didehydrothymidine Monophosphate (CycloSald4TMP): Synthesis and Antiviral Evaluation of a New d4TMP Delivery System. J. Med. Chem., 41, 1417-1427 (1998).
124. Melcher, A., Todryk, S., Hardwick, N., Ford, M, Jacobson, M., and Vile, R. G., Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4, 581-587 (1998).
125. Melton, R. G. and Sherwood, R. F., Antibody-enzyme conjugates for cancer therapy. Journal of the National Cancer Institute, 88, 153 (1996).
126. Melton, R. G., Searle, F., Sherwood, R. F., Bagshawe, K. D., and Boden, J. A., The potential of carboxypeptidase G2 antibody conjugates as anti-tumour agents. II. In vivo localizing and clearance properties in a choriocarcinoma model. Br. J. Cancer, 61, 420-424 (1990).
127. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H., Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93, 1831-1835 (1996).
128. Moolten, F. L., Tumor chemotherapy conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46, 5276-5281 (1986).
129. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M., Tumor expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor . Cancer Res., 54, 1503-1506 (1994).
130. rd International Feline Retrovirus Research Symposium 1996, Fort Collins, Col. USA.
131. Nassens, L., Balazarini, J., and De Clerq, E., Therapeutic potential of PMEA as an antiviral drug. Med. Virol., 4, 147-159 (1993).
132. Niculescu-Duvaz, I. and Springer, C. J., Development of prodrugs for ADEPT (antibody-directed prodrug therapy). Expert Opinion on Investigational Drugs. 3, 289 (1996).
133. O'Malley, B. W. Jr., Chen, S. H., Schwartz, M. R., and Woo, S. L., Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res., 55, 1080-1085 (1995).
134. Palomino, E., Kessel, D., and Horwitz, J. P., A Dihydropyridine Carriers System for Sustained Delivery of 2′,3′-Dideoxynucleosides to the Brain. J. Med. Chem., 32, 622 (1989).
135. Pandha, H. S., Martin, L. A., Rigg, A., Hurst, H. C., Stamp, G. W., Sikora, K., and Lemoine, N. R., J. Clin. Oncol., 17, 2180-2189 (1999).
136. Pannecoucke, X., Parmentier, G., Schmitt, G., Dolle, F., and Luu, B., Synthesis of the Phosphodiester of 3β(7β-Hydroxy-cholestrol) and of 5′(3′Deoxy, 3Azido-thymidine). Tetrahedron, 50, 1173-1178 (1994).
137. Pantaleo, G., Graziosi, C., Demarest, J. F., Butini, L., Montroni, M., Fox, C. H., Orenstein, J. M., Kotler, D. P., and Fauci, A. S., HIV Infection is Active and Progressive in Lymphoid Tissue During the Clinical Latent Stage of Disease. Nature, 392, 355-358 (1993).
138. Périgaud, C., Aubertin, A.M., Benzaria, S., Pélicano, H., Girardet, J. L., Maury, G., Gosselin, G., Kirn, A., and Imbach, J. L., Equal Inhibition of the Replication of Human Immunodeficiency Virus in Human T-Cell Culture by ddA Bis (SATE) Phosphotriester and 3-Azido-2′,3′- dideoxythymidine Biochem. Pharmacol., 48, 11-14 (1994).
139. Périgaud, C., Girardet, J. L., Lefebvre, I., Xie, M. Y., Aubertin, A. M., Kirn, A., Gosselin, G., Imbach, J. L., and Sommadossi, J. P., Comparison of Cytotoxicity of Mononucleoside Phosphotriester Derivatives Bearing Biolabile Phosphate Protecting Groups in Normal Human Bone Marrow Progenitor Cells. Antiviral Chem. Chemother., 7, 338-345 (1996).
140. Périgaud, C., Gosselin, G., Benzaria, S., Girardet, J. L., Maury, G., Pélicano, H., Aubertin, A. M., Kirn, A., and Imbach, J. L., Bis(S-Acyl-2Thioethyl)esters of 2′,3′-Dideoxyadenosine 5′-Monophosphate are Potent Anti-HIV Agents in Cell Culture. Nucleosides & Nucleotides, 14, 789-791 (1995).
141. Périgaud, C., Gosselin, G., and Imbach, J. L., Minireview: from the Pronucleotide Concept to the SATE Phosphate Protecting Groups. Curr. Topics in Med. Chem., 2, 15-29 (1997).
142. Peuch, F., Gosselin, G., Lefebvre, I., Pompon, A., Aubertin, A. M., Kirn, A., and Imbach, J. L., Intracellular Delivery of Nucleoside Monophosphates Through a Reductase-Mediated Activation Process. Antiviral Res., 22, 155-174 (1993).
143. Pompon, A., Lefebvre, I., Imbach, J. -L., Khan, S., and Farquhar, D.; Antiviral Chem. Chemother., 5, 91-98 (1994).
144. Procopiou, P. A., Biggadike, K., English, A. F., Farrell, R. M., Hagger, G. N., Hancock, A. P., Haase, M. V., Irving, W. R., Sareen, M., Snowden, M. A., Solanke, Y. E., Tralau-Stewart, C. J., Walton, S., and Wood, J. A., Novel glucocorticoid antedrugs possessing a 17β-(γ-lactone) ring . J. Med. Chem., 44, 602-612 (2001).
145. Pue, M. A. and Benet, L. Z., Pharmacokinetics of Famciclovir in Man. Antiviral Chem. Chemother., 4 (Suppl. 1), 47-55 (1993).
146. Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., Katz, D., Blease, R. M., and Oldfield, E. H., Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 12, 1354-1361 (1997).
147. Rivera, G., Rhomes, J. A., Dahl, G. V., Pratt, C. B., Wood, A., and Avery, T. L., Combined VM-26 and Cytosine Arabinoside in Treatment of Refractory Childhood Lymphocytic Leukemia. Cancer, 45, 1284 (1980).
148. Roche, E. B., Design of Biopharmaceutical Properties through Prodrugs and Analogs. Academy of Pharmaceutical Sciences Symposium, Washington DC (1977).
149. Rogers, G. T., Burke, P. J., Shama, S. K., Koodie, R., and Boden, J. A., Plasma clearance of an antibody-enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Br. J. Cancer, 72, 1357-1363 (1995).
150. Rolan, P., Pharmacokinetics of New Antiherpetic Agents. Clin. Pharmacokinet., 29, 333-340 (1995).
151. Sakai, A., Mori, N., Shuto, S., Suzuki, T., Deacylation-Reacylation Cycle: A Possible Absorption Mechanism for the Novel Lymphotropic Antitumor Agent Dipalmitoylphosphatidyl-fluorouridine in Rats. J. Pharm. Sci., 83, 575-578 (1993).
152. Sastry, J. K., Nehete, P. N., Khan, S., Nowak, B. J., Plunkett, W., Arlinghaus, R. B., and Farquhar, D., Membrane-Permeable Dideoxyuridine 5-Monophosphate Analogue Inhibits Human Immunodeficiency Virus Infection. Mol. Pharmacol., 41, 441-445 (1992).
153. Shama, S. K., Bagshawe, K. D., Burke, P. J., Boden, R. W., and Rogers, G. T., Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localization in a xenograft model. Br. J. Cancer, 61, 659-662 (1990).
154. Shama, S. K., Bagshawe, K. D., Springer, C. J., Burke, P. J., Rogers, G. T., Boden, J. A., Antoniw, P., Melton, R. G., and Sherwood, R. F., Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis. Marker, 9, 225-231 (1991).
155. Shama, S. K., Boden, J. A., Springer, C. J., Burke, P. J., and Bagshawe, K. D., Antibody-directed enzyme prodrug therapy (ADEPT). A three phase study in ovarian tumor xenografts. Cell. Biophys., 24, 219-228 (1994).
156. Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A. G., and Barbier, N., A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with herpes simplex thymidine kinase gene followed by ganciclovir. Hum. Gene Ther., 10, 2325-2335 (1999).
157. Sharma, A. P., Ollapally, A. P., and Lee, H. J., Synthesis and Anti-HIV Activity of Prodrugs of Azidothymidine. Antiviral Chem. Chemother., 4, 93-96 (1993).
158. Sherwood, R., Melton, R., Alwan, S., and Hughes, P., Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur. J. Biochem., 148, 447-453 (1985).
159. Shlipak, M. G., Simon, J. A., Vittinghoff, E., Lin, F., Barrett-Conner, E., Knopp, R. H., Levy, R. I., and Hulley, S. B., Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. JAMA, 283, 1845-1852 (2000).
160. Shuto, S., Itoh, H., Obara, T., Nakagami, K., Yaso, M., Yaginuma, S., Tsujino, M., and Saito, T. New Neplanocin Analogues II. Enzymatic One-Step Synthesis and Antitumor Activity of 6′-(3-sn-Phosphatidyl)Neplanocin a Derivatives. Nucleosides & Nucleotides, 11, 437-446 (1992).
161. Shuto, S., Itoh, H.; Ueda, S., Imamura, S., Fukukawa, K., Tsujino, M., Matsuda, A., and Ueda, T., A Facile Enzymatic Synthesis of 5′-(3-sn- Phosphatidyl)nucleosides and Their Antileukemic Activities. Chem. Pharm. Bull., 36, 209-217 (1988).
162. Siddiqui, A. Q., Ballatore, C., McGuigan, C., De Clerq, E., and Balzarini, J., The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure-Activity Relationship. J. Med. Chem., 42, 393-399 (1999).
163. Siemers, N. O., Kerr, D. E., Yarnold, S., Stebbins, M., Vrudhula, V. M., Hellstrom, I., Hellstrom, K. E., and Senter, P. D., Construction, expression, and activities of L49-sFv b-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjug. Chem., 8, 510-519 (1997).
164. Smythe, W. R., Hwang, H. C., Elshami, A. A., Amin, K. M., Eck, S. L., Davidson, B. L., Wilson, J. M., Kaiser, L. R., and Albelda, S. M., Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg., 222, 78-86 (1995).
165. Soliman, M. R. I., and Lee, H. J., Anti-inflammatory activity of acid ester derivatives of prednisolone. Res. Comm. Chem. Path. Pharm., 33(2), 357-360 (1981).
166. Springer, C. J. and Niculescu-Duvaz, I., Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv. Drug Deliv. Rev., 22, 351-364 (1996).
167. Springer, C. J., Dowell, R., Burke, P. J., Hadley, E., Davies, D. H., Blakey, D. C., Melton, R. G., and Niculescu-Duvaz, I., Optimization of alkylating agent prodrugs derived from phenol nad aniline mustards: a new clincal candidate prodrug (ZD 2767) for antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem., 38, 5051-5065 (1995).
168. Srinivas, R. V., Robbins, B. L., Connelly, M. C., Gong, Y.-F., Bischofberger, N., and Fridland, A., Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates. Antimicrob. Agents Chemother., 37, 2247-2250 (1993).
169. Starrett, J. E., Jr., Tortolani, D. R., Russel, J., Hitchcock, M. J. M., Whiterock, V., Martin, J. C., and Mansuri, M. M., Synthesis, Oral Bioavailability Determination, and In Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomehtoxy)-ethyl]adenine (PMEA). J. Med. Chem., 37, 1857-1864 (1994).
170. Stribbling, S. M., Friedlos, F., Martin, J., Davies, L., Spooner, R. A., Marais, R., and Springer, C. J., Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hm. Gene Ther., 11, 258-292 (2000).
171. Suzuki, T., Sato, E., Tada, H., and Tojima, Y., Examination of local anti-inflammatory activities of new steroids, hemisuccinyl methyl glycolates. Biol. Pharm. Bull., 22(8), 816-821 (1999a).
172. Suzuki, T., Tada, H., Sato, E., and Tojima, Y., Examination on biological activities and fates of new steroids, steroid-17-yl methyl glycolates derivatives. Tohoku J. Exptl. Med., 187(2), 127-140 (1999b).
173. Svensson, H. P., Frank, I. S., Berry, K. K., and Senter, P. D., Therapeutic effects of monoclonal antibody-b-lactamase conjugates in combination with a nitrogen mustard anticacer prodrug in models of human renal cell carcinoma. J. Med. Chem., 41, 1507-1512 (1998).
174. Svensson, H. P., Kadow, J. F., Vrudhula, V. M., Wallace, P. M. and Senter, P. D., Monoclonal antibody-b-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug. Chem., 3, 176-181 (1992).
175. Tanaka, T., Kanai, F., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H., Shiratori, Y., Lan, K.-H., Ishitobi, M., and Omata, M., Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res., 56, 1341-1345 (1996).
176. Terrence, P. F., Kinjo, J. E., Lesiak, K., Balazarine, J., and De Clerq, E., AIDS Dementia: Synthesis and Properties of a Derivative of 3-Azido-3-Deoxythymidine (AZT) That May Become Locked in the Central Nervous System. FEBS Lett., 234, 135 (1988).
177. Timofeevski, S. L., Panarin, E. F., Vinogradov, O. L., and Nezhentsev, M. V., Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Pharm. Res., 13(3), 476-480 (1996).
178. Tokunaga, Y., Iwasa, T., Fujisaki, J., Sawai, S., and Kagayama, A., Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. Antitumor Activity of Newly Synthesized Lipophilic 1-β-D- Arabinofuranosylcytosine Prodrug-Bearing Liposomes. Chem. Pharm. Bull., 36, 3574-3583 (1988a).
179. Tokunaga, Y., Iwasa, T., Fujisaki, J., Sawai, S., and Kagayama, A., Liposomal Sustained-Release Delivery Systems for IntravenousInjection. III. AntitumorActivity of Lipophilic Mitomycin C Prodrug Bearing Liposomes. Chem. Pharm. Bull., 36, 3565 (1988b).
180. Topf, N., Worgall, N. R., Hackett, N. R., and Crystal, R. G., Regional 'prodrug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther., 5, 507-513 (1998).
181. Torrence, P. F., Kinjo, J., Khamnei, S., and Greig, N. H., Synthesis and Pharmacokinetics of a Dihydropyridine Chemical Delivery System for the Antiimmunodeficiency Virus Agent Dideoxycytidine. J. Med. Chem., 36, 529-537 (1993).
182. Touraine, R. L., Vahanian, N., Ramsey and W. J., Blaese, R. M., Enhancement of the herpes simplex virus thymidine kinase ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther., 9, 2385-2391 (1998).
183. Tsai, C. C., Follis, K. E., Beck, and T. W., Sabo, A., Bischofberger, N., Dailey, P. J., Effects of (R)-9-(2-Phosphonylmethoxypropyl) adenine Monotherapy on Chronic SIV Infection in Macaques. AIDS Research and Human Retroviruses, 13, 707-712 (1997).
184. Tsai, C. C., Follis, K. E., Sabo, A., Beck, T. W., Grant, R. F., Bischofberger, N., Benveniste, R. E., and Black, R., Prevention of SIV Infection in Macaques by ( R)-9-(2-Phosphonylmethoxypropyl) adenine. Science, 270, 1197-1199 (1995).
185. Uchida, K., Krieis, W., Distribution of 1-β-D- Arabinofuranosylcytosine, Cytidine and Deoxycytidine in Mice Bearing ara-C Sensitive and Resistant P815 Neoplasms. Biochem. Pharmacol., 18, 1115 (1969).
186. Valette, G., Pompon, A., Giradet, J. L., Gosselin, G., Périgaud, C., Gosselin, G., and Imbach, J. L., Decomposition Pathways and in vitro HIV Inhibitory Effects of IsoddA Pronucleotides: Toward a Rational Approach for Intracellular Delivery of Nucleoside 5-Monophosphates. J. Med. Chem., 39, 1981-1990 (1996).
187. Van Rompay, K. K. A., Cherrington, J. M., Marthas, M. L., Berardi, C. J., Mulato, A. S., Spinner, A., Tarara, R. P., Canfield, D. R., Telm, S., Bischofberger, N., and Pederson, N. C., 9-[2-(Phosphomethoxy)propyl]-adenine Therapy of Established Simian Immunodeficiency Virus Infection in Infant Rhesus Macaques . Antimicrob. Agents Chemother., 40, 2586-2591 (1996).
188. Vere Hodge, R. A., Sutton, D., Boyd, M. R., Harnden, M. R., and Jarvest, R. L., Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpesvirus Agent BRL 39123 [9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine; Penciclovir]. Antimicrob. Agents Chemother., 33, 1765-1773 (1989).
189. Vrudhula, V. M., Svensson, H. P., Kennedy, K. A., Senter, P. D., and Wallace, P. M., Antitumor activities of a cephalosporin prodrug combination with monoclonal antibody-b-lactamase conjugates. Bioconjug. Chem., 4, 334-340 (1993).
190. st National Conference on Human Retroviruses and Related Infections, Washington DC (1993).
191. Wei, S. J., Chao, Y., Shih, Y. L., Yang, D. M., Hung, Y. M., and Yang, W. K., Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase. Gene Ther., 6, 420-431 (1999).
192. Whitley, R. J. and Gnann, J. W., Acyclovir: A Decade Later. N. Engl. J. Med., 327, 782-788 (1992).
193. Xie, H., Voronkov, M., Liotta, D. C., Korba, B. A., Schinazi, R. F., Richman, D. D., Hostetler, K. Y., Phosphatidyl-2′,3′-dideoxy- 3′-thiacytidine: Synthesis and Antiviral Activity in Hepatitis Band HIV-1 Infected Cells. Antiviral Res., 28, 113-120 (1995).
194. Yoon, K.-J., Khalil, M. A., Kwon, T. Choi, S.-J., and Lee, H. J., Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16α-alkoxycarbonyl-17-deoxyprednisolone derivatives. Steroids, 60, 445-451 (1995).
195. You, Z., Heiman, A. S., Chen, M., and Lee, H. J., Novel steroid spiro enones: Consideration of prednisolone derivatives with diethyl oxalate. Steroids, 65, 109-115 (2000).
196. You, Z., Khalil, M. A., Ko, D.-H., and Lee, H. J., Suppression of the Mattox rearrangement of 16α-cyanoprednisolones in acid: synthesis of methyl 16α-prednisolone carboxylates. Tetrahedron Lett., 36(19), 3303-3306 (1995).